1. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24week, double-blind, randomized Phase 3 trial 
Eli M. Roth, Marja-Riitta Taskinen, Henry N. Ginsberg, John J.P. Kastelein, Helen M. Colhoun, Jennifer G. Robinson, Laurence Merlet, Robert Pordy, Marie T. Baccara-Dinet 
International Journal of Cardiology 
Volume 176, Issue 1, Pages (September 2014)
DOI: /j.ijcard
Copyright © 2014 The Authors Terms and Conditions

2. Fig 1
Study design.
Although the protocol called for an LDL-C threshold of ≥100mg/dL for up-titration, a threshold of ≥70mg/dL was applied in error in a blinded manner in this study. Arrows along the bottom of the figure indicate assessment times. EOT=end of treatment; EZE=ezetimibe; LDL-C=low-density lipoprotein cholesterol; NCEP-ATP III, National Cholesterol Education Program Adult Treatment Panel III; Q2W=every 2 weeks; R=randomization; W=week.
International Journal of Cardiology  , 55-61DOI: ( /j.ijcard )
Copyright © 2014 The Authors Terms and Conditions

3. Fig 2 Patient disposition.
*Life events made continuing too difficult. ITT=intent-to-treat; LDL-C=low-density lipoprotein cholesterol.
International Journal of Cardiology  , 55-61DOI: ( /j.ijcard )
Copyright © 2014 The Authors Terms and Conditions

4. Fig 3
LDL-C levels (mg/dl) versus study time point (on-treatment analysis).
Values above week 12 and week 24 data points indicate LS mean (SE) % change from baseline. LDL-C=low-density lipoprotein cholesterol; LS=least squares; SE=standard error.
International Journal of Cardiology  , 55-61DOI: ( /j.ijcard )
Copyright © 2014 The Authors Terms and Conditions